WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Exosome Diagnostics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
ginkgo biowork | November 11, 2021
ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...
Felix Biotechnology, Inc. | November 06, 2020
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, Inc., a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter ...
TumorGen Inc. and PhenoVista Biosciences LLC | September 09, 2022
TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology. This achievement is a critical milestone in developing anti-metastatic drugs, called “cluster busters,” which will target these cells and prevent cancer metastasis. “Anti-metastatic therapies that can stop tumors fro...
Medical
PR Newswire | October 12, 2023
Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With t...
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE